tiprankstipranks
Advertisement
Advertisement

ARVN Stock Latest News

Arvinas Earnings Call: VEPPANU Win, Pipeline Momentum
Company AnnouncementsArvinas Earnings Call: VEPPANU Win, Pipeline Momentum
18h ago
ARVN
Arvinas price target raised to $16 from $14 at BofA
PremiumThe Fly
Arvinas price target raised to $16 from $14 at BofA
7d ago
PFE
ARVN
Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target
PremiumRatings
Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target
7d ago
ARVN
Arvinas price target raised to $18 from $16 at BTIG
PremiumThe Fly
Arvinas price target raised to $18 from $16 at BTIG
8d ago
ARVN
RIGL
Arvinas price target raised to $20 from $18 at Barclays
PremiumThe Fly
Arvinas price target raised to $20 from $18 at Barclays
8d ago
ARVN
Arvinas Faces Key Commercialization Risk as VEPPANU’s Success Hinges on Third‑Party Partner with Pfizer
PremiumCompany AnnouncementsArvinas Faces Key Commercialization Risk as VEPPANU’s Success Hinges on Third‑Party Partner with Pfizer
8d ago
ARVN
Arvinas Earnings Call: PROTAC Breakthrough and New Risks
Premium
Company Announcements
Arvinas Earnings Call: PROTAC Breakthrough and New Risks
8d ago
ARVN
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
Premium
The Fly
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
8d ago
PFE
ARVN
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
PremiumThe Fly
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
8d ago
PFE
ARVN
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer
PremiumThe Fly
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer
9d ago
PFE
ARVN
Arvinas Grants Rigel Global Rights to VEPPANU Therapy
PremiumCompany Announcements
Arvinas Grants Rigel Global Rights to VEPPANU Therapy
9d ago
8K
ARVN
Arvinas reports Q1 EPS (90c), consensus (63c)
PremiumThe Fly
Arvinas reports Q1 EPS (90c), consensus (63c)
9d ago
ARVN
Arvinas management to meet with BTIG
PremiumThe FlyArvinas management to meet with BTIG
16d ago
ARVN
Guardant Health receives FDA approval for Guardant360 CDx
Premium
The Fly
Guardant Health receives FDA approval for Guardant360 CDx
17d ago
GH
PFE
Arvinas price target raised to $24 from $21 at Citi
Premium
The Fly
Arvinas price target raised to $24 from $21 at Citi
17d ago
ARVN
Arvinas Gains First FDA Approval for Breast Cancer Drug
PremiumCompany Announcements
Arvinas Gains First FDA Approval for Breast Cancer Drug
19d ago
8K
ARVN
Arvinas gets early approval for Vepdeg, says Truist
PremiumThe Fly
Arvinas gets early approval for Vepdeg, says Truist
19d ago
ARVN
Arvinas trading resumes
PremiumThe Fly
Arvinas trading resumes
19d ago
ARVN
Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC
PremiumThe Fly
Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC
19d ago
PFE
ARVN
Arvinas trading halted, news pending
PremiumThe FlyArvinas trading halted, news pending
19d ago
ARVN
Arvinas Buy Rating Driven by Robust ARV-102 LRRK2 Degrader Data and Clear Neurodegeneration Development Path
Premium
Ratings
Arvinas Buy Rating Driven by Robust ARV-102 LRRK2 Degrader Data and Clear Neurodegeneration Development Path
2M ago
ARVN
Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating
Premium
Ratings
Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating
2M ago
ARVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >